Study #2023-0645
Open-label, single center, single-arm, phase 2 study of neoadjuvant pembrolizumab in combination with carboplatin and paclitaxel in patients with stage 1 cT1cN0M0 Triple Negative Breast Cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Carboplatin, Paclitaxel, Pembrolizumab, Doxorubicin, Cyclophosphamide
Description
To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Study phase:
Phase II
Physician name:
Oluchi Oke
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-844-961-3045
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.